Cargando…

Development of Novel Patient-Reported Outcome (PRO) and Observer-Reported Outcome (ObsRO) Instruments in Retinitis Pigmentosa (RP) and Leber Congenital Amaurosis (LCA): ViSIO-PRO and ViSIO-ObsRO

INTRODUCTION: Retinitis pigmentosa (RP) and Leber congenital amaurosis (LCA) are rare inherited retinal degenerative disorders resulting in visual impairments and impacts on patients’ vision-dependent activities of daily living (ADL), mobility and distal health-related quality of life (HRQoL). This...

Descripción completa

Detalles Bibliográficos
Autores principales: Audo, Isabelle, Patalano, Francesco, Naujoks, Christel, Spera, Claudio, Fischer, M. Dominik, Green, Jane, Kay, Christine, Durham, Todd, Williamson, Nicola, Bradley, Helena, Barclay, Melissa, Boparai, Kieran, Banhazi, Judit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10287847/
https://www.ncbi.nlm.nih.gov/pubmed/37210697
http://dx.doi.org/10.1007/s40123-023-00724-x
_version_ 1785061957946048512
author Audo, Isabelle
Patalano, Francesco
Naujoks, Christel
Spera, Claudio
Fischer, M. Dominik
Green, Jane
Kay, Christine
Durham, Todd
Williamson, Nicola
Bradley, Helena
Barclay, Melissa
Boparai, Kieran
Banhazi, Judit
author_facet Audo, Isabelle
Patalano, Francesco
Naujoks, Christel
Spera, Claudio
Fischer, M. Dominik
Green, Jane
Kay, Christine
Durham, Todd
Williamson, Nicola
Bradley, Helena
Barclay, Melissa
Boparai, Kieran
Banhazi, Judit
author_sort Audo, Isabelle
collection PubMed
description INTRODUCTION: Retinitis pigmentosa (RP) and Leber congenital amaurosis (LCA) are rare inherited retinal degenerative disorders resulting in visual impairments and impacts on patients’ vision-dependent activities of daily living (ADL), mobility and distal health-related quality of life (HRQoL). This study aimed to conduct qualitative research to understand the patient experience of RP/LCA across genotypes and inform development of patient- and observer-reported outcome (PRO/ObsRO) instruments in RP/LCA. METHODS: Research activities included a qualitative literature review and review of existing visual function PRO instruments in RLBP1 RP, and concept elicitation (CE) and cognitive debriefing (CD) interviews of existing PRO instruments with patients with RLBP1 RP, expert clinicians, and payers. In wider RP/LCA, a social media listening (SML) study and a qualitative literature review was conducted, while psychometric evaluation of a PRO instrument in LCA was performed. Input from expert clinicians was sought at key stages. RESULTS: Findings from the qualitative literature reviews identified a range of visual function symptoms which had significant impacts on patients’ vision-related ADL and distal HRQoL. Patient interviews identified additional visual function symptoms and impacts not previously reported in published literature. These sources informed development and refinement of a conceptual model displaying the patient experience of RP/LCA. Review of existing visual function PRO instruments, and CD interviews evaluating their content validity, confirmed that no existing instrument provides a comprehensive assessment of all concepts relevant to patients with RP/LCA. This highlighted the need for development of the Visual Symptom and Impact Outcomes PRO and ObsRO instruments to adequately assess the patient experience of RP/LCA. CONCLUSIONS: Results informed and supported development of the instruments to assess visual functioning symptoms and vision-dependent ADL, mobility and distal HRQoL in RP/LCA, in accordance with regulatory standards. Next steps to further support use in RP/LCA clinical trials/practice includes content and psychometric validation of the instruments in this population. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40123-023-00724-x.
format Online
Article
Text
id pubmed-10287847
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-102878472023-06-24 Development of Novel Patient-Reported Outcome (PRO) and Observer-Reported Outcome (ObsRO) Instruments in Retinitis Pigmentosa (RP) and Leber Congenital Amaurosis (LCA): ViSIO-PRO and ViSIO-ObsRO Audo, Isabelle Patalano, Francesco Naujoks, Christel Spera, Claudio Fischer, M. Dominik Green, Jane Kay, Christine Durham, Todd Williamson, Nicola Bradley, Helena Barclay, Melissa Boparai, Kieran Banhazi, Judit Ophthalmol Ther Original Research INTRODUCTION: Retinitis pigmentosa (RP) and Leber congenital amaurosis (LCA) are rare inherited retinal degenerative disorders resulting in visual impairments and impacts on patients’ vision-dependent activities of daily living (ADL), mobility and distal health-related quality of life (HRQoL). This study aimed to conduct qualitative research to understand the patient experience of RP/LCA across genotypes and inform development of patient- and observer-reported outcome (PRO/ObsRO) instruments in RP/LCA. METHODS: Research activities included a qualitative literature review and review of existing visual function PRO instruments in RLBP1 RP, and concept elicitation (CE) and cognitive debriefing (CD) interviews of existing PRO instruments with patients with RLBP1 RP, expert clinicians, and payers. In wider RP/LCA, a social media listening (SML) study and a qualitative literature review was conducted, while psychometric evaluation of a PRO instrument in LCA was performed. Input from expert clinicians was sought at key stages. RESULTS: Findings from the qualitative literature reviews identified a range of visual function symptoms which had significant impacts on patients’ vision-related ADL and distal HRQoL. Patient interviews identified additional visual function symptoms and impacts not previously reported in published literature. These sources informed development and refinement of a conceptual model displaying the patient experience of RP/LCA. Review of existing visual function PRO instruments, and CD interviews evaluating their content validity, confirmed that no existing instrument provides a comprehensive assessment of all concepts relevant to patients with RP/LCA. This highlighted the need for development of the Visual Symptom and Impact Outcomes PRO and ObsRO instruments to adequately assess the patient experience of RP/LCA. CONCLUSIONS: Results informed and supported development of the instruments to assess visual functioning symptoms and vision-dependent ADL, mobility and distal HRQoL in RP/LCA, in accordance with regulatory standards. Next steps to further support use in RP/LCA clinical trials/practice includes content and psychometric validation of the instruments in this population. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40123-023-00724-x. Springer Healthcare 2023-05-21 2023-08 /pmc/articles/PMC10287847/ /pubmed/37210697 http://dx.doi.org/10.1007/s40123-023-00724-x Text en © The Author(s) 2023 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Original Research
Audo, Isabelle
Patalano, Francesco
Naujoks, Christel
Spera, Claudio
Fischer, M. Dominik
Green, Jane
Kay, Christine
Durham, Todd
Williamson, Nicola
Bradley, Helena
Barclay, Melissa
Boparai, Kieran
Banhazi, Judit
Development of Novel Patient-Reported Outcome (PRO) and Observer-Reported Outcome (ObsRO) Instruments in Retinitis Pigmentosa (RP) and Leber Congenital Amaurosis (LCA): ViSIO-PRO and ViSIO-ObsRO
title Development of Novel Patient-Reported Outcome (PRO) and Observer-Reported Outcome (ObsRO) Instruments in Retinitis Pigmentosa (RP) and Leber Congenital Amaurosis (LCA): ViSIO-PRO and ViSIO-ObsRO
title_full Development of Novel Patient-Reported Outcome (PRO) and Observer-Reported Outcome (ObsRO) Instruments in Retinitis Pigmentosa (RP) and Leber Congenital Amaurosis (LCA): ViSIO-PRO and ViSIO-ObsRO
title_fullStr Development of Novel Patient-Reported Outcome (PRO) and Observer-Reported Outcome (ObsRO) Instruments in Retinitis Pigmentosa (RP) and Leber Congenital Amaurosis (LCA): ViSIO-PRO and ViSIO-ObsRO
title_full_unstemmed Development of Novel Patient-Reported Outcome (PRO) and Observer-Reported Outcome (ObsRO) Instruments in Retinitis Pigmentosa (RP) and Leber Congenital Amaurosis (LCA): ViSIO-PRO and ViSIO-ObsRO
title_short Development of Novel Patient-Reported Outcome (PRO) and Observer-Reported Outcome (ObsRO) Instruments in Retinitis Pigmentosa (RP) and Leber Congenital Amaurosis (LCA): ViSIO-PRO and ViSIO-ObsRO
title_sort development of novel patient-reported outcome (pro) and observer-reported outcome (obsro) instruments in retinitis pigmentosa (rp) and leber congenital amaurosis (lca): visio-pro and visio-obsro
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10287847/
https://www.ncbi.nlm.nih.gov/pubmed/37210697
http://dx.doi.org/10.1007/s40123-023-00724-x
work_keys_str_mv AT audoisabelle developmentofnovelpatientreportedoutcomeproandobserverreportedoutcomeobsroinstrumentsinretinitispigmentosarpandlebercongenitalamaurosislcavisioproandvisioobsro
AT patalanofrancesco developmentofnovelpatientreportedoutcomeproandobserverreportedoutcomeobsroinstrumentsinretinitispigmentosarpandlebercongenitalamaurosislcavisioproandvisioobsro
AT naujokschristel developmentofnovelpatientreportedoutcomeproandobserverreportedoutcomeobsroinstrumentsinretinitispigmentosarpandlebercongenitalamaurosislcavisioproandvisioobsro
AT speraclaudio developmentofnovelpatientreportedoutcomeproandobserverreportedoutcomeobsroinstrumentsinretinitispigmentosarpandlebercongenitalamaurosislcavisioproandvisioobsro
AT fischermdominik developmentofnovelpatientreportedoutcomeproandobserverreportedoutcomeobsroinstrumentsinretinitispigmentosarpandlebercongenitalamaurosislcavisioproandvisioobsro
AT greenjane developmentofnovelpatientreportedoutcomeproandobserverreportedoutcomeobsroinstrumentsinretinitispigmentosarpandlebercongenitalamaurosislcavisioproandvisioobsro
AT kaychristine developmentofnovelpatientreportedoutcomeproandobserverreportedoutcomeobsroinstrumentsinretinitispigmentosarpandlebercongenitalamaurosislcavisioproandvisioobsro
AT durhamtodd developmentofnovelpatientreportedoutcomeproandobserverreportedoutcomeobsroinstrumentsinretinitispigmentosarpandlebercongenitalamaurosislcavisioproandvisioobsro
AT williamsonnicola developmentofnovelpatientreportedoutcomeproandobserverreportedoutcomeobsroinstrumentsinretinitispigmentosarpandlebercongenitalamaurosislcavisioproandvisioobsro
AT bradleyhelena developmentofnovelpatientreportedoutcomeproandobserverreportedoutcomeobsroinstrumentsinretinitispigmentosarpandlebercongenitalamaurosislcavisioproandvisioobsro
AT barclaymelissa developmentofnovelpatientreportedoutcomeproandobserverreportedoutcomeobsroinstrumentsinretinitispigmentosarpandlebercongenitalamaurosislcavisioproandvisioobsro
AT boparaikieran developmentofnovelpatientreportedoutcomeproandobserverreportedoutcomeobsroinstrumentsinretinitispigmentosarpandlebercongenitalamaurosislcavisioproandvisioobsro
AT banhazijudit developmentofnovelpatientreportedoutcomeproandobserverreportedoutcomeobsroinstrumentsinretinitispigmentosarpandlebercongenitalamaurosislcavisioproandvisioobsro